CenterBook Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

CenterBook Partners’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.14M	Buy	+273,253	New	+$5.52M	0.24%	103

Other funds holding SNDX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Vienna Insurance Group Warsaw, Poland $466M AUM 97.31% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Torray Investment Partners Bethesda, Maryland $758M AUM 24.76% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

CenterBook Partners's SNDX Position: Q3 2026 in Review

CenterBook Partners opened a new position in Syndax Pharmaceuticals (SNDX) in Q3 2026: 273,253 shares worth $5.14M. The stake represents 0.24% of the portfolio and ranks #103 among its holdings.

73 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

CenterBook Partners held 273,253 shares of Syndax Pharmaceuticals worth $5.14M as of Q3 2026.
Syndax Pharmaceuticals was a new CenterBook Partners position in Q3 2026.
Syndax Pharmaceuticals made up 0.24% of CenterBook Partners's portfolio in Q3 2026, its #103 holding.
73 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.